Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Interleukin-2 for Vascular Inflammation in ACS
NCT04241601Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2020
- Primary completion
- Jan 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in acute coronary syndrome (ACS), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Aug 2020; status: completed.
02
Drugs
aldesleukin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04241601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241601.